The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor

The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor

.

Saved in:

Bibliographic Details
Main Author:	article Editorial
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2023-03-01
Series:	Педиатрическая фармакология
Online Access:	https://www.pedpharma.ru/jour/article/view/2274
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

The FDA has approved the first treatment for Friedreich's ataxia
by: article Editorial
Published: (2023-05-01)

The FDA has Approved Bozutinib for Children with Chronic Myelogenous Leukemia
by: article Editorial
Published: (2023-11-01)

The FDA has approved the first medical drug for Rett syndrome
by: article Editorial
Published: (2023-05-01)

THE FDA HAS APPROVED A NEW ANTIBIOTIC FOR THE TREATMENT OF UTIS
by: article Editorial
Published: (2025-05-01)

FDA HAS APPROVED THE LIQUID ADHD MEDICATION (NOT A STIMULANT)
by: article Editorial
Published: (2024-07-01)

THE FDA HAS APPROVED THE FIRST VACCINE AGAINST THE CHIKUNGUNYA VIRUS
by: article Editorial
Published: (2023-12-01)

THE FDA HAS APPROVED DUPILUMAB FOR THE PEDIATRIC TREATMENT OF ESOPHAGEAL DISEASES
by: article Editorial
Published: (2024-02-01)

THE FDA HAS APPROVED THE TRIPLE COMBINATION TOPICAL ACNE REMEDY
by: article Editorial
Published: (2023-12-01)

FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
by: article Editorial
Published: (2021-12-01)

FDA Has Approved First Drug for Treatment of Congenital Athymia
by: article Editorial
Published: (2021-12-01)

FDA HAS APPROVED NEW DRUG TREATMENT FOR HIV IN CHILDREN
by: article Editorial
Published: (2024-05-01)

FDA HAS APPROVED THE FIRST THERAPY FOR NEUROENDOCRINE TUMORS IN CHILDREN
by: article Editorial
Published: (2024-07-01)

The FDA has approved a new drug for the treatment of leukemia
by: article editorial
Published: (2024-12-01)

THE FDA HAS APPROVED A NEW COMBINED MENINGOCOCCAL VACCINE
by: article Editorial
Published: (2025-05-01)

Intraocular infections following biologicals and Janus Kinase inhibitors
by: Parthopratim Dutta Majumder, et al.
Published: (2025-08-01)

THE FDA HAS APPROVED A NEW TREATMENT FOR HEMOPHILIA A OR B
by: Article Editorial
Published: (2024-11-01)

FDA HAS APPROVED THE FIRST MEDICATION FOR RARE IMMUNITY-RELATED DISEASES
by: article Editorial
Published: (2024-07-01)

FDA HAS ASSIGNED RMAT STATUS TO RETT SYNDROME GENE THERAPY
by: article Editorial
Published: (2024-07-01)

FDA HAS APPROVED NEW DRUG TREATMENT FOR DUCHENE MUSCULAR DYSTROPHY
by: article Editorial
Published: (2024-05-01)

Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
by: Grace Xiong, BHSc, et al.
Published: (2025-04-01)

The FDA has approved the first gene therapy for the treatment of Duchennel's muscular dystrophy
by: article Editorial
Published: (2023-08-01)

The FDA has approved the first medical drug for the treatment of primary immunodeficiency APDS
by: article Editorial
Published: (2023-05-01)

THE FDA HAS APPROVED THE THE FIRST DRUG FOR THE CONGENITAL FORM OF THROMBOTIC THROMBOCYTOPENIC PURPURA
by: article Editorial
Published: (2023-12-01)

FDA Has Approved First Long-Acting Growth Hormone Preparation for Children
by: article Editorial
Published: (2021-12-01)

Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
by: Luo Y, et al.
Published: (2025-05-01)

THE FDA HAS APPROVED TWO GENE THERAPY DRUGS FOR THE TREATMENT OF SICKLE CELL ANEMIA
by: article Editorial
Published: (2024-02-01)

THE FDA HAS APPROVED A DRUG AGAINST NIEMANN–PICK DISEASE, TYPE C
by: Article Editorial
Published: (2024-11-01)

FOR THE FIRST TIME, THE FDA HAS APPROVED A GEL FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM AT HOME
by: article Editorial
Published: (2024-02-01)

The FDA has approved a new drug for adolescents and adults with severe focal alopecia
by: article Editorial
Published: (2023-08-01)

Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?
by: Sarah E. Packer, et al.
Published: (2025-08-01)

Janus kinase inhibitors for alopecia areata: a review of clinical data
by: Yutong Sun, et al.
Published: (2025-05-01)

FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01)

Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis
by: Bai-lin Chen, et al.
Published: (2024-12-01)

THE FDA HAS APPROVED THE FIRST DRUG FOR PEOPLE WITH PRADER – WILLI SYNDROME IN MEMORY OF A COLLEAGUE
by: article Editorial
Published: (2025-05-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
by: E. L. Nasonov, et al.
Published: (2019-03-01)

Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
by: E. L. Nasonov, et al.
Published: (2022-05-01)

When topicals fall short, oral Janus kinase inhibitors offer a needed solution in chronic hand eczema
by: Christopher G. Bunick, MD, PhD
Published: (2025-10-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)